Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06104306 · ClinicalTrials.gov registry record · Phase 4

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

A Phase 4 study of HIV-1-infection, sponsored by Gilead Sciences.

Completed
Registry status
Phase 4
Development phase
33
Enrollment target
18
Study locations

NCT06104306 is a Phase 4 study of HIV-1-infection that has completed, run by Gilead Sciences. The registered enrollment target is 33 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 18 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06104306, a Phase 4 study of HIV-1-infection, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 4
Development phase
33 participants
Enrollment target
18
Study locations

Study Summary

The goal of this clinical study is to learn how safe it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels. The primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12.

Conditions Studied

HIV-1-infection

Interventions

  • DRUG B/F/TAF

Study Locations (18)

Other

  • Hamilton Health Sciences-SIS Clinic - Hamilton
  • St. Michael's Hospital - Toronto
  • University Health Network - Toronto General Hospital - Toronto
  • CHU Bordeaux - Hopital Saint-Andre - Bordeaux
  • APHM - Hospital Sainte Marguerite - Marseille
  • CHR Orleans - Orléans
  • Centre Hospitalier Annecy Genevois - Pringy
  • HU de Strasbourg - Nouvel Hopital Civil - Strasbourg

California

  • Franco Felizarta, MD - Bakersfield
  • BIOS Clinical Research - Palm Springs
  • UC San Diego AntiViral Research Center (AVRC) - San Diego

Florida

  • Midway Immunology and Research Center - Ft. Pierce
  • Bliss Health - Orlando

Indiana

  • Indiana University Infectious Diseases Research - Indianapolis

Massachusetts

  • Boston Medical Center - Boston

Nevada

  • Las Vegas Research Center - Las Vegas

New Jersey

  • Saint Michael's Medical Center - Newark

Washington

  • MultiCare Rockwood Main Clinic - Spokane

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-12-13
Est. Completion 2025-04-23
Phase Phase 4

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06104306

The ClinicalTrials.gov registry entry for NCT06104306 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which B/F/TAF is the first listed.

NCT06104306 reports 18 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06104306 about?

NCT06104306 is a clinical study titled "Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)". The goal of this clinical study is to learn how safe it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants wi...

What is the current status of trial NCT06104306?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2023-12-13. Estimated completion is 2025-04-23.

What conditions does trial NCT06104306 study?

This clinical trial studies the following conditions: HIV-1-infection.

What interventions are being tested in trial NCT06104306?

The interventions under investigation include: B/F/TAF (DRUG).

Who is sponsoring clinical trial NCT06104306?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06104306 being conducted?

This trial has 18 study locations across California, Florida, Indiana, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV-1-infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.